Generic for Saxenda – What Is Liraglutide?

Last Updated On: June 2, 2025

Generic medicines make up nearly 90% of prescriptions dispensed in the United States, providing more affordable alternatives without compromising on safety or effectiveness. This accessibility is especially critical for managing chronic conditions where consistent treatment is essential, but cost can be a significant barrier.

One such medication that has gained widespread attention for chronic weight management is Saxenda. Given the high cost of brand-name drugs, many patients and healthcare providers are curious about the availability of a generic version.

In this article, we will explore the generic name for Saxenda, explain what liraglutide is, and discuss how it compares to its brand-name counterpart in terms of effectiveness, FDA approval, and availability. This information aims to help patients make informed decisions about their treatment options.

Key Takeaways

• Liraglutide is the active ingredient in both Saxenda and Victoza, but the two medications have different formulations, dosages, and approved uses—Saxenda for weight management and Victoza for type 2 diabetes.
• Saxenda is currently the only FDA-approved medication for chronic weight management containing liraglutide; no generic Saxenda is yet approved in the U.S. for obesity treatment.
• Several pharmaceutical companies are developing liraglutide biosimilars, primarily for diabetes, but none are yet approved for weight management.
• The cost of Saxenda remains high, though manufacturer assistance programs can help reduce out-of-pocket expenses for eligible patients.
• The impending patent expiration of Saxenda in 2025 may lead to more affordable generic options, increasing accessibility for obesity treatment.
• Patients should consult healthcare providers for guidance on insurance coverage, medication use, and emerging treatment alternatives to ensure the best outcomes.

About: Operating since 2016, Med Supply Solutions is known for being one of the industry’s top and trusted suppliers of cosmetic and viscosupplementation products. If you’re looking to buy Saxenda online, contact our sales department for more information.  

What Is Liraglutide, the Active Ingredient of Saxenda?

Liraglutide is a synthetic analog of the body’s natural GLP-1 hormone. It functions by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying. These combined effects help regulate blood sugar levels and reduce appetite, making liraglutide effective for both type 2 diabetes and chronic weight management.

As the key active ingredient in both Victoza and Saxenda, liraglutide plays a critical role in treating metabolic diseases. Despite sharing the same molecule, the two medications differ in formulation, dosage, and approved uses. Notably, the Saxenda manufacturer developed the product specifically to aid in weight loss, distinguishing it from Victoza’s primary focus on glycemic control.

Like other injectable medications, it is essential to understand how to handle Saxenda properly, which includes addressing common questions such as, “Does Saxenda need to be refrigerated?” Proper storage maintains liraglutide’s effectiveness throughout the treatment course.

Saxenda vs. Victoza: Key Differences

Though Saxenda and Victoza contain liraglutide, they serve distinct therapeutic purposes:

Because of these differences, patients should never substitute one medication for the other without consulting their healthcare provider. Using the wrong formulation or dosage could reduce efficacy or cause adverse effects.

Regulatory and Patent Status

Saxenda’s patent is set to expire in August 2025, potentially opening the door for generic alternatives specifically for weight management. However, as of now, no generic Saxenda has been approved in the United States, meaning the branded medication remains the only available option for obesity treatment.

In contrast, Victoza’s patent expired in late 2023, resulting in the availability of generic liraglutide versions approved for the management of type 2 diabetes. These generics are not approved for weight loss or obesity treatment, emphasizing the importance of using the correct medication for the intended indication.

This distinction underscores that generic liraglutide is indication-specific, and until a Saxenda generic is formally approved for weight management, patients should continue using the branded product under medical supervision.

Availability of Biosimilars or Equivalents

Biosimilars are biologic drugs that closely mimic original biologics like liraglutide, offering potential cost savings and broader access. Multiple pharmaceutical companies have developed or are developing liraglutide biosimilars, primarily for diabetes treatment.

For example:

• Glenmark Pharmaceuticals has launched a liraglutide biosimilar in India approved for type 2 diabetes but not for obesity.
• Most biosimilars currently in development do not yet have approval for weight management indications.

Regulatory authorities require biosimilars to demonstrate equivalent safety and efficacy before approving them for any specific use. As such, none are currently authorized as replacements for Saxenda in the U.S. for chronic weight management.

Patients seeking liraglutide treatment for obesity should continue using Saxenda and await future biosimilar approvals specific to this indication.

Cost, Coverage, and Prescribing Implications

The price of Saxenda is one of the most common concerns for patients considering this weight The cost of Saxenda remains a major consideration for many patients. Without insurance, monthly expenses typically range from $1,200 to $1,500, which can be a barrier to access and long-term adherence.

• Insurance coverage varies widely. Many commercial insurers require prior authorization, including BMI thresholds, documented weight-related comorbidities, and prior failed attempts at weight loss through lifestyle modifications.
• Manufacturer savings programs, offered by Novo Nordisk, can reduce out-of-pocket costs for eligible patients with private insurance, though government programs like Medicare and Medicaid often exclude these benefits.
• The pending introduction of generic Saxenda post-patent expiration is expected to drive cost reductions and increase accessibility, as was seen with Victoza generics in diabetes care.

Physicians often weigh financial factors alongside clinical considerations when prescribing Saxenda, sometimes opting for alternative treatments or assistance programs to improve patient adherence and outcomes.

Conclusion

Liraglutide is a proven, effective treatment for both type 2 diabetes and obesity management. While generic versions of liraglutide are available for diabetes, a generic Saxenda for weight management has not yet been approved in the U.S.

As patents expire and biosimilars advance through regulatory pathways, more affordable options for obesity treatment are anticipated. Until then, patients should utilize available support programs, consult healthcare providers for insurance guidance, and stay informed about emerging treatment options.

Understanding the nuances of brand-name Saxenda, its storage requirements, and the distinctions from generics is crucial to ensure safe, effective, and compliant weight management therapy.

FAQs

1. Is there a generic version of Saxenda available?

 As of now, no generic version of Saxenda is approved for weight management in the U.S.

2. Can I use a generic version of liraglutide for weight loss?

Generic liraglutide is approved for diabetes treatment, not for weight management. Using it off-label for weight loss should only be done under medical supervision.

3. When will a Saxenda generic be available?

Saxenda’s patent is set to expire in August 2025, after which generic versions may become available, pending regulatory approval.

4. Will the cost of Saxenda decrease once a generic is available?

Typically, the introduction of generic versions leads to reduced prices, making treatments more affordable.

FAQs

Association for Accessible Medicines. Report: 2023 U.S. Generic and Biosimilar Medicines Savings Report. Published April 10, 2025. https://accessiblemeds.org/resources/reports/2023-savings-report-2/

Generic Drug Facts. U.S. Food And Drug Administration. Published November 1, 2021. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts

Saxenda for Weight Loss, Dosage & Side Effects. Drugs.com. https://www.drugs.com/saxenda.html